• About
  • Subscribe
  • Advertise
  • Contact
Monday, June 23, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

TGA approves first pharma option for proliferative diabetic retinopathy

by Myles Hume
September 22, 2020
in Local, Macular disease, News, Therapies
Reading Time: 2 mins read
A A
geographic atrophy Australia

The approval is based on results from the Phase 3 OAKS and DERBY studies at 24 months.

Share on FacebookShare on Twitter

For 40 years laser therapy has been the standard treatment for proliferative diabetic retinopathy (PDR), but now Australian ophthalmologists have a new option following regulatory approval of an existing drug.

Novartis has announced the Therapeutic Goods Administration approval of Lucentis (ranibizumab) for treating PDR in adults. It is the first pharmacological therapy in Australia for the vision-threatening complication of diabetes – and the sixth indication for Lucentis.

Until now, panretinal laser photocoagulation (PRP) has been the standard treatment for PDR but can result in permanent side effects, and negatively impact peripheral vision, affecting the ability to carry out daily activities, such as driving.

Regulatory approval of Lucentis was based on findings from a multicentre, randomised, active-controlled, parallel-assignment, non-inferiority phase 3 study in which 305 patients with PDR, with or without diabetic macular oedema (DME) at baseline, were enrolled. The study compared ranibizumab 0.5 mg intravitreal injections to standard treatment with PRP.

The findings were supported by pooled data from three key Novartis studies demonstrating that Lucentis led to an improvement in the diabetic retinopathy severity scale (DRSS).

Analysis of results at two years, with an additional follow-up with 66% of study participants at five years, favoured Lucentis over laser treatment and indicated a potential to prevent PDR disease progression.

Clinical Associate Professor of Sydney University and vitreoretinal ophthalmologist and surgeon, Dr Andrew Chang, said ophthalmologists welcome the TGA approval of Lucentis in treating blindness in patients suffering from diabetes.

“Study data shows that Lucentis is effective for improving the severity of retinopathy and treating complications due to proliferative retinopathy in addition to macular oedema,” he said.

Statistics show diabetic retinopathy (DR) is one of the top five causes of irreversible blindness among Australian adults and the leading cause of blindness amongst working age adults worldwide.

In can worsen over time from the non-proliferative form (NPDR) to the vision-threatening form, PDR. Without treatment, approximately 50% of people with very severe NPDR progress to PDR within a year and 25% of people who have had diabetes for 15 years will have PDR.

Macular Disease Foundation Australia (MDFA) CEO Ms Dee Hopkins welcomed the new indication for Lucentis “which provides another option for patients and their clinicians to treat this sight-threatening condition”.

While Lucentis is listed on the Pharmaceutical Benefits Scheme for several conditions including neovascular age-related macular degeneration and diabetic macular edema, it is not currently listed for PDR.

More reading

TGA approves Luxturna gene therapy

Novartis provides safety update for Beovu

Tags: ApprovalAustraliaDr Andrew ChangLucentisNovartispanretinal laser photocoagulationPDRproliferative diabetic retinopathyranibizumabTherapeutic Goods Administration

Related Posts

Dominique Jorgensen believes those willing to learn new skills are a major workplace asset, with adaptability the key to succeeding in any practice setting. Image: Dominique Jorgensen.

When the student becomes the teacher

by Staff Writer
June 23, 2025

MEMBER PROFILE: Name: Dominique Jorgensen Position: Optical dispensing instructor, University of Western Australia’s Department of Optometry and Vision Sciences Location:...

Dr William Blase assessing scans obtained on the Optos MonacoPro. Images: Image: California Eye Professionals & Optos.

Early insights into the new Optos MonacoPro

by Staff Writer
June 23, 2025

Optos’ latest system is so new that Insight took its search global to find an ophthalmologist who has installed the...

Collective bargaining on consult times and KPIs are a focus of the group. Image: H_Ko/stock.adobe.com.

Hundreds of optometrists have joined Health Services Union

by Staff Writer
June 19, 2025

Hundreds of Australian optometrists have signed up to the Health Services Union (HSU) in the past few months, according to...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited